Christopher James Frankenfield is CFO at Xilio Therapeutics, Inc. (XLO). They have made 1 open-market trade across 1 company since 2025, most recently 2026-01-02.
CIK 0001988344
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XLO | 31,796 | $279K |
Shares reported on the most recent Form 4, priced at the 2026-01-05 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.